vialroom

#retatrutide 2024-12-01

Sunday45 messages10 participantstimes are UTC
Highlights from this day
  • mg_per_ml — i log resting heart rate every morning because of this and its the one number i actually watch 16:02
  • amylin_amy — the heart rate thing is real enough that i mention it whenever someone asks about starting 16:34
  • warsaw_vial — research use only is on every vial and i treat it as exactly that, nobody here is prescribing 17:03
  • split_dose_sam — phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan 19:53
  • VialBot — Batch lookup E-2205: 3 independent reports on file, earliest 2024-08-09. 21:28
LL

is the GI worse than tirzepatide or about the same

❤️2📉3📈2
MP

the half life supports weekly dosing and thats what ive done from the start

settled by month three

glucagon is the new bit

🙏1

low and slow

i log resting heart rate every morning because of this and its the one number i actually watch

🧊1🎉15📈1

the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial

low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

my resting heart rate is up about 3 bpm, did that settle for anyone

mine went up too

anyone logging resting heart rate on this

AA

did the phase 2 plateau or was it still moving at the end

🧊4
AA

the heart rate thing is real enough that i mention it whenever someone asks about starting

medutest-report-b-0114.pdf
3 pages · 878 KB · not retained in the public archive
MP

nobody should read my log as a plan, im recording what i did and thats all it is

[edited]
GB

right so im at 12 and the appetite effect is stronger than i expected, normal

MP

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists
phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

WV

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

watching my heart rate

MP

back after 7 months, has anything actually been published since

MP

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely

GB

follow up blood pressure stayed flat for me while heart rate moved, which i didnt expect

MP

sorry to jump in whats the half life like, is it weekly the same way

LL

did the phase 2 result actually come in higher than the tirzepatide numbers

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me

GB

how do people square the research use only framing with logging their own use

quick one how slow is low and slow here, four weeks a step or longer

MP

appetite suppression at 7.5 was stronger than my tirzepatide experience at a comparable point

SD

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

update on the earlier thing people insist on small steps because the side effects arrive faster than on the other two

came off at 16 weeks because my resting rate stayed elevated and i didnt like it

MP

whats a sensible starting point, im seeing everything from 0.5 to 2

does the glucagon arm explain the heart rate or is that unrelated

VB

Batch lookup E-2205: 3 independent reports on file, earliest 2024-08-09.

3
SD

my resting rate went up 5 bpm in the first month and came back most of the way by month 24